Geographical variation in Plasmodium vivax relapse

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Battle, Katherine E ^a   Karhunen, Markku S ^a   Bhatt, Samir ^a   Gething, Peter W ^a   Howes, Rosalind E ^a   Golding, Nick ^a   Van Boeckel, Thomas P ^b   Messina, Jane P ^a   Shanks, G Dennis ^c   Smith, David L ^d,e   Baird, J Kevin ^f,g   Hay, Simon I ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PRINCETON UNIVERSITY   (United States)

^c AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Malaria; Map; Periodicity; Plasmodium vivax; Recrudescence; Recurrence; Relapse; Strain

Indexed keywords

CHLOROQUINE; MEFLOQUINE; MEPACRINE; PRIMAQUINE;

ADAPTATION; ARTICLE; DISEASE CARRIER; ECOLOGY; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFECTION; META ANALYSIS (TOPIC); NONHUMAN; PARASITE TRANSMISSION; PERIODICITY; PHENOTYPE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RELAPSE; SEASONAL VARIATION; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT FAILURE;

GEOGRAPHY; HUMANS; INCIDENCE; MALARIA, VIVAX; PERIODICITY; PLASMODIUM VIVAX; RECURRENCE;

EID: 84899586276     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-144     Document Type: Article

References (90)

1. The economic and social burden of malaria. Sachs J, Malaney P, Nature 2002 415 680 685 10.1038/415680a 11832956 (Pubitemid 34136401)
2. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. Gething PW, Elyazar IRF, Moyes CM, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HFL, Price RN, Mueller I, Baird JK, Hay SI, PLoS Negl Trop Dis 2012 6 1814 10.1371/journal. pntd.0001814 22970336
3. The global public health significance of Plasmodium vivax. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI, Adv Parasitol 2012 80 1 111 23199486
4. The pathophysiology of vivax malaria. Anstey NM, Russell B, Yeo TW, Price RN, Trends Parasitol 2009 25 220 227 10.1016/j.pt.2009.02.003 19349210
5. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti, Elyazar I, Bangs MJ, Maguire JD, Baird JK, Am J Trop Med Hyg 2007 77 984 991 17984364 (Pubitemid 351837852)
6. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, Umana KG, Vemuri R, Okoseray MJ, Penttinen PM, Ebsworth P, Sugiarto P, Anstey NM, Tjitra E, Price RN, Malar J 2008 7 148 10.1186/1475-2875-7-148 18673572
7. Plasmodium vivax malaria. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A, Emerg Infect Dis 2005 11 132 134 10.3201/eid1101.040519 15705338 (Pubitemid 40093368)
8. Vivax malaria: neglected and not benign. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, Am J Trop Med Hyg 2007 77 79 87 18165478
9. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, PLoS Med 2008 5 128 10.1371/journal.pmed.0050128 18563962 (Pubitemid 351919110)
10. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I, PLoS Med 2008 5 127 10.1371/journal.pmed.0050127 18563961 (Pubitemid 351919109)
11. Vivax malaria: a major cause of morbidity in early infancy. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN, Clin Infect Dis 2009 48 1704 1712 10.1086/599041 19438395
12. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN, Clin Infect Dis 2008 46 1374 1381 10.1086/586743 18419439 (Pubitemid 351589936)
13. Eliminating malaria-all of them. Baird JK, Lancet 2010 376 1883 1885 10.1016/S0140-6736(10)61494-8 21035840
14. Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Bockarie MJ, Dagoro H, Malar J 2006 5 15 10.1186/1475-2875-5-15 16504027
15. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Bousema T, Drakeley C, Clin Microbiol Rev 2011 24 377 410 10.1128/CMR.00051-10 21482730
16. Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. Luxemburger C, Perea WA, Delmas G, Pruja C, Pecoul B, Moren A, Trans R Soc Trop Med Hyg 1994 88 155 159 10.1016/0035-9203(94)90273-9 8036656 (Pubitemid 24139670)
17. The neglected burden of Plasmodium vivax malaria. Mendis K, Sina BJ, Marchesini P, Carter R, Am J Trop Med Hyg 2001 64 97 106 11425182 (Pubitemid 32552576)
18. Plasmodium vivax transmission: chances for control? Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L, Trends Parasitol 2004 20 192 198 10.1016/j.pt.2004.02.001 15099559 (Pubitemid 38526134)
19. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Wells TN, Burrows JN, Baird JK, Trends Parasitol 2010 26 145 151 10.1016/j.pt.2009.12.005 20133198
20. Pampana E, A textbook of malaria eradication London: Oxford University Press 1969
21. Ranking of elimination feasibility between malaria-endemic countries. Tatem AJ, Smith DL, Gething PW, Kabaria CW, Snow RW, Hay SI, Lancet 2010 376 1579 1591 10.1016/S0140-6736(10)61301-3 21035838
22. Plasmodium vivax blood-stage dynamics. McKenzie FE, Jeffery GM, Collins WE, J Parasitol 2002 88 521 535 10.1645/0022-3395(2002)088[0521:PVBSD]2.0.CO;2 12099421 (Pubitemid 34686515)
23. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NP, Singhasivanon P, White NJ, Kaker F, Malar J 2010 9 105 10.1186/1475-2875-9-105 20409302
24. Artemisinin combination therapy for vivax malaria. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, Lancet Infect Dis 2010 10 405 416 10.1016/S1473-3099(10)70079-7 20510281
25. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652 (Pubitemid 46335820)
26. On the infectiousness of patients infected with Plasmodium vivax and Plasmodium falciparum. Boyd MF, Kitchen SF, Am J Trop Med Hyg 1937 s1-17 253 262
27. Experimental infection of Anopheles farauti with different species of Plasmodium. Collins WE, Sullivan JS, Nace D, Williams T, Sullivan JJ, Galland GG, Grady KK, Bounngaseng A, J Parasitol 2002 88 295 298 10.1645/0022-3395(2002) 088[0295:EIOAFW]2.0.CO;2 12054000 (Pubitemid 34493395)
28. Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax. Gething PW, Van Boeckel TP, Smith DL, Guerra CA, Patil AP, Snow RW, Hay SI, Parasit Vectors 2011 4 92 10.1186/1756-3305-4-92 21615906
29. Relapse in malaria-an enigma. Coatney GR, J Parasitol 1976 62 3 9 815536
30. Malaria parasites of man: life-cycles and morphology (excluding ultrastructure). Garnham PC, Malaria: Principles and practice of malariology Edinburgh, UK: Churchill Livingstone 1989 61 96
31. The hypnozoite and malarial relapse. Krotoski WA, Prog Clin Parasitol 1989 1 1 19 2491691
32. Primaquine therapy for malaria. Baird JK, Hoffman SL, Clin Infect Dis 2004 39 1336 1345 10.1086/424663 15494911 (Pubitemid 39458520)
33. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Galappaththy GN, Omari AA, Tharyan P, Cochrane Database Syst Rev 2007 1 D004389 17253504
34. The global pipeline of new medicines for the control and elimination of malaria. Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN, Malar J 2012 11 316 10.1186/1475-2875-11-316 22958514
35. G6PD deficiency. Beutler E, Blood 1994 84 3613 3636 7949118 (Pubitemid 24362456)
36. Glucose-6-phosphate dehydrogenase deficiency. Cappellini MD, Fiorelli G, Lancet 2008 371 64 74 10.1016/S0140-6736(08)60073-2 18177777
37. WHO, Guidlines for the treatment of malaria, Second Edition Geneva, Switzerland: World Health Organization 2010
38. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, Snow RW, PLoS Med 2010 7 1000290 10.1371/journal.pmed.1000290 20563310
39. Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation. Patil AP, Okiro EA, Gething PW, Guerra CA, Sharma SK, Snow RW, Hay SI, Malar J 2009 8 186 10.1186/1475-2875-8-186 19656373
40. Recrudescence and relapse in vivax malaria. Coatney GR, Cooper WC, Proceedings of the 4th International Congress on Tropical Medicine 1948 1 629 639
41. A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Garnham PC, Bray RS, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Sergiev PG, Tiburskaja NA, Shute PG, Maryon M, Bull World Health Organ 1975 52 21 32 764993
42. Long latency in Plasmodium vivax infections in a temperate zone. Winckel CWF, Doc Med Geog Trop 1955 7 292 298
43. Plasmodium vivax. Coatney GR, Collins WE, Contacos PG, The Primate Malarias Bethesda, MD: U.S. National Institute of Allergy and Infectious Diseases 1971 43 67
44. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, Del Portillo HA, Lancet Infect Dis 2009 9 555 566 10.1016/S1473-3099(09)70177-X 19695492
45. Can primaquine therapy for vivax malaria be improved? Baird JK, Rieckmann KH, Trends Parasitol 2003 19 115 120 10.1016/S1471-4922(03)00005-9 12643993 (Pubitemid 36338074)
46. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, Trans R Soc Trop Med Hyg 1976 70 474 481 10.1016/0035-9203(76)90132-2 320726 (Pubitemid 8034799)
47. Determinants of relapse periodicity in Plasmodium vivax malaria. White NJ, Malar J 2011 10 297 10.1186/1475-2875-10-297 21989376
48. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Douglas NM, Nosten F, Ashley EA, Phaiphun L, Van Vugt M, Singhasivanon P, White NJ, Price RN, Clin Infect Dis 2011 52 612 620 10.1093/cid/ciq249 21292666
49. The activation of vivax malaria hypnozoites by infectious diseases. Shanks GD, White NJ, Lancet Infect Dis 2013 13 900 906 10.1016/S1473-3099(13) 70095-1 23809889
50. Geography of malaria. A medico-geographic profile of an ancient disease. Lysenko AJ, Semashko IN, Itogi Nauki: Medicinskaja Geografija Moscow: Academy of Sciences, USSR, Lebedew AW, 1968 25 146
51. Quantifying effect of geographic location on epidemiology of Plasmodium vivax malaria. Lover AA, Coker RJ, Emerg Infect Dis 2013 19 1058 1065 10.3201/eid1907.121674 23763820
52. Macdonald G, The Epidemiology and Control of Malaria London: Oxford University Press 1957
53. An update of Wallace's zoogeographic regions of the world. Holt B, Lessard JP, Borregaard MK, Fritz SA, Araujo MB, Dimitrov D, Fabre PH, Graham CH, Graves GR, Jonsson KA, Nogues-Bravo D, Wang ZH, Whittaker RJ, Fjeldsa J, Rahbek C, Science 2013 339 74 78 10.1126/science.1228282 23258408
54. Updated world map of the Koppen-Geiger climate classification. Peel MC, Finlayson BL, McMahon TA, Hydrol Earth Sys Sci 2007 11 1633 1644 10.5194/hess-11-1633-2007 (Pubitemid 47581348)
55. Terrestrial ecoregions of the worlds: a new map of life on Earth. Olson DM, Dinerstein E, Wikramanayake ED, Burgess ND, Powell GVN, Underwood EC, D'Amico JA, Itoua I, Strand HE, Morrison JC, Loucks CJ, Allnutt TF, Ricketts TH, Kura Y, Lamoreux JF, Wettengel WW, Hedao P, Kassem KR, Bioscience 2001 51 933 938 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2 (Pubitemid 33072658)
56. PubMed http://www.ncbi.nlm.nih.gov/pubmed/
57. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, Adv Parasitol 2013 81 133 201 23384623
58. Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria. Cooper WC, Myatt AV, Hernandez T, Jeffery GM, Coatney GR, Am J Trop Med Hyg 1953 2 949 957 13104803
59. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA, Ann Trop Med Parasitol 1999 93 809 812 10.1080/00034989957790 10715673 (Pubitemid 30058079)
60. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Alvarez G, Pineros JG, Tobon A, Rios A, Maestre A, Blair S, Carmona-Fonseca J, Am J Trop Med Hyg 2006 75 605 609 17038680 (Pubitemid 46941262)
61. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T, Lancet 1987 2 1052 1055 2889965
62. Studies on the chemotherapy of the human malarias; the antimalarial activity of quinacrine. Taggart JV, Earle DP Jr, Berliner RW, Welch WJ, Zubrod CG, Jailer JW, Kuhn BH, Norwood J, Shannon JA, J Clin Invest 1948 27 93 97 10.1172/JCI101979
63. Chloroquine resistance in Plasmodium vivax. Baird JK, Antimicrob Agents Chemother 2004 48 4075 4083 10.1128/AAC.48.11.4075-4083.2004 15504824 (Pubitemid 39434858)
64. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Guerra CA, Hay SI, Lucioparedes LS, Gikandi PW, Tatem AJ, Noor AM, Snow RW, Malar J 2007 6 17 10.1186/1475-2875-6-17 17306022 (Pubitemid 46332961)
65. Google Maps https://maps.google.com/
66. ESRI, ArcGIS Desktop 10.0 Redlands, CA: Environmental Systems Resource Institute 2010
67. Bias and efficiency of meta-analytic variance estimators in the random-effects model. Viechtbauer W, J Educ Behav Stat 2005 30 261 293 10.3102/10769986030003261 (Pubitemid 41538934)
68. Conducting meta-analyses in R with the metafor package. Viechtbauer W, Journal of Statistical Software 2010 36 1 48
69. R Core Team, R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing 2013
70. Analyzing effect sizes: random effects models. Raudenbush SW, The handbook of research synthesis and meta-analysis New York: Russell Sage Foundation, Cooper H, Hedges LV, Valentine JC, 2 2009 295 315
71. Transformations related to the angular and the square root. Freeman MF, Tukey JW, Ann Math Stat 1950 21 607 611 10.1214/aoms/1177729756
72. Clayton D, Hills M, Statistical Models in Epidemiology Oxford, UK: Oxford University Press 2013
73. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Ulm K, Am J Epidemiol 1990 131 373 375 2296988 (Pubitemid 20118904)
74. Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico. Gonzalez-Ceron L, Mu J, Santillan F, Joy D, Sandoval MA, Camas G, Su X, Choy EV, Torreblanca R, Parasit Vectors 2013 6 109 10.1186/1756-3305-6-109 23597046
75. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L, Lancet 2014 383 1049 1058 10.1016/S0140-6736(13)62568-4 24360369
76. Role of An. culicifacies and An. stephensi in malaria transmission in urban Delhi. Sharma SN, Subbarao SK, Choudhury DS, Pandey KC, Indian J Malariol 1993 30 155 168 8131883
77. The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic precis. Sinka ME, Bangs MJ, Manguin S, Chareonviriyaphap T, Patil AP, Temperley WH, Gething PW, Elyazar IR, Kabaria CW, Harbach RE, Hay SI, Parasit Vectors 2011 4 89 10.1186/1756-3305-4-89 21612587
78. The evolutionary history of Plasmodium vivax as inferred from mitochondrial genomes: parasite genetic diversity in the Americas. Taylor JE, Pacheco MA, Bacon DJ, Beg MA, Machado RL, Fairhurst RM, Herrera S, Kim JY, Menard D, Povoa MM, Villegas L, Mulyanto, Snounou G, Cui L, Zeyrek FY, Escalante AA, Mol Biol Evol 2013 30 2050 2064 10.1093/molbev/mst104 23733143
79. Natural history of Korean vivax malaria after deliberate inoculation of human volunteers. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, J Lab Clin Med 1954 44 723 726 13212248
80. Studies in human malaria. VIII. The protective and therapeutic action of quinacrine against St. Elizabeth strain vivax malaria. Cooper WC, Ruhe DS, Coatney CR, Josephson ES, Young MD, Am J Hyg 1949 49 25 40 18108518
81. The course of infection caused by the North Korean strain of Plasmodium vivax. Tiburskaja NA, Vrublevskaja OS, In WHO Malaria Report 1977 1977 895 1 19 1-19
82. Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Mueller I, Galinski MR, Tsuboi T, Arevalo-Herrera M, Collins WE, King CL, Adv Parasitol 2013 81 77 131 23384622
83. Concerning the pathogenesis of relapses in malarial fevers. Bignami A, South Med J 1913 6 79 89 10.1097/00007611-191302000-00002
84. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Price RN, Douglas NM, Anstey NM, Curr Opin Infect Dis 2009 22 430 435 10.1097/QCO.0b013e32832f14c1 19571748
85. Plasmodium vivax resistance to chloroquine? Rieckmann KH, Davis DR, Hutton DC, Lancet 1989 2 1183 1184 2572903 (Pubitemid 19275451)
86. The influence of sporozoite dosage in vivax malaria. Boyd MF, Am J Trop M 1940 20 279 286
87. Studies in human malaria. XVIII. The life pattern of sporozoite-induced St Elizabeth strain vivax malaria. Coatney GR, Cooper WC, YM D, Burgess RW, Am J Epidemiol 1950 51 200 215
88. Findlay GM, Recent advances in chemotherapy Philadelphia, USA: The Blakiston Company 1951
89. Clinical trials of anti-malarial drugs. Most H, Internal Medicine in World War II, Infectious Diseases, vol 2. Volume 2 Washington, D.C.: Office of the Surgeon General, Department of the Army 1963 479 492
90. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Coatney GR, Alving AS, Jones R Jr, Hankey DD, Robinson DH, Garrison PL, Coker WG, Donovan WN, Di Lorenzo A, Marx RL, Simmons IH, Am J Trop Med Hyg 1953 2 985 988 13104808